-
Elan Pharma International Limited v. Abraxis Bioscience Inc. DC
- 1:06-cv-00438
- D. Del.
- Judge: Gregory M. Sleet
- Filed: 07/19/2006
- Closed: 03/02/2011
- Latest Docket Entry: 01/08/2019
- PACER
1
Plaintiff
1
Defendant
1
Accused
Product
2
Patents-in-Suit
1,688
Days in
Litigation
-
Elan Pharma International Limited v. Abraxis Bioscience Inc. DC
- 1:06-cv-00438
- D. Del.
- Judge: Gregory M. Sleet
- Filed: 07/19/2006
- Closed: 03/02/2011
- Latest Docket Entry: 01/08/2019
- PACER
Cause of Action
Willful Patent Infringement
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A method of administering a nanoparticulate composition to a mammal without eliciting adverse hemodynamic effects comprising intravenously administering to said mammal an effective amount of a nanoparticulate drug composition at an infusion rate
view more
|
Enforceable and Valid (112)
Entry 614 Entry 613 |
2 |
The method of claim 1 wherein the effective average particle size of said drug is from about 50 to about 400 nm.
|
Enforceable and Valid (112)
Entry 614 Entry 613 |
3 |
The method of claim 1 wherein said drug is an organic therapeutic substance.
|
Enforceable and Valid (112)
Entry 614 Entry 613 |
13 |
A method of administering a nanoparticulate composition to a mammal without eliciting adverse hemodynamic effects comprising intravenously administering to said mammal an effective amount of a nanoparticulate drug composition at an infusion rate
view more
|
Enforceable and Valid (112)
Entry 614 Entry 613 |
14 |
The method of claim 13 wherein the effective average particle size of said drug is of from about 50 to about 400 nm.
|
Enforceable and Valid (112)
Entry 614 Entry 613 |
15 |
The method of claim 13 wherein said drug is an organic therapeutic substance.
|
Enforceable and Valid (112)
Entry 614 Entry 613 |
Claim # | Claim Text | Outcome |
---|---|---|
1 |
Particles consisting essentially of 99.9% by weight of a crystalline medicament useful in treating cancer susceptible to treatment with said medicament, said medicament having a solubility in water of less than 10 mg/ml, and having a
view more
|
Enforceable and Valid (112)
Entry 613 Entry 614 |
3 |
The particles of claim 1 having an average effective particle size of less than 300 nm.
|
Enforceable and Valid (112)
Entry 614 Entry 613 |
5 |
The particles of claim 1 wherein said anticancer agent is selected from the group consisting of piposulfan, piposulfam, camptothecin, etoposide, taxol, 1,2,4-benzotriazin-3-amine 1,4-dioxide, 1,2,4-benzotriazin-7-amine 1,4-dioxide and retinoic
view more
|
Enforceable and Valid (112)
Entry 614 Entry 613 |
10 |
In a method of treating a mammal comprising administering to the mammal an effective amount of an anticancer agent, the improvement wherein the efficacy of said anticancer agent is increased by administering said anticancer agent in the form of
view more
|
Enforceable and Valid (112)
Entry 613 Entry 614 |
11 |
In a method of treating a mammal comprising administering to the mammal an effective amount of an anticancer agent, the improvement wherein the toxicity of said anticancer agent is reduced by administering said anticancer agent in the form of the
view more
|
Enforceable and Valid (112)
Entry 613 Entry 614 |
-
Infringement
Abraxis Bioscience Incorporated
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Abraxane | US 5,399,363 A |
3, 5
|
Infringement
Entry 614Entry 613 |
-
Damages